PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Estrogen-lowering drugs reduce mastectomy rates for breast cancer patients

Estrogen-lowering drugs reduce mastectomy rates for breast cancer patients
2011-05-10
(Press-News.org) In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

Patients with these larger breast tumors have two options, says Matthew J. Ellis, MD, PhD, of Washington University School of Medicine in St. Louis and principal investigator of the trial conducted by the American College of Surgeons Oncology Group. "One option is to undergo mastectomy. The second is to receive medication before surgery to reduce the size of the tumor so that breast-conserving surgery becomes possible," he says.

Those who choose the second option usually receive chemotherapy. But now, Ellis and colleagues have shown that post-menopausal women with estrogen-receptor positive breast cancer can benefit from a class of drugs called aromatase inhibitors that lower the amount of estrogen in the body. Since estrogen-receptor positive breast cancers feed off estrogen, aromatase inhibitors can slow or stop the growth of these tumors in women who have undergone menopause.

Though estrogen no longer comes from the ovaries, post-menopausal women still make small amounts of estrogen with the enzyme aromatase. Aromatase inhibitors block this enzyme, eliminating the body's remaining estrogen. Because aromatase inhibitors don't stop the ovaries from making estrogen, they only work in post-menopausal women.

The results appear online May 9, in the Journal of Clinical Oncology.

Of the 159 women in the trial who were originally told they required mastectomy, 81 or slightly more than half saw sufficient tumor shrinkage after 16 weeks of aromatase inhibitor treatment to undergo breast-conserving surgery instead.

"At the beginning, all of these patients were going to get mastectomy and at the end of the trial only half got mastectomy," says Ellis, also an oncologist who treats patients at the Alvin J. Siteman Cancer Center at Washington University and Barnes-Jewish Hospital. "That's a very substantial improvement in surgical outcomes."

In addition, of the 189 women originally considered "marginal" for breast conservation (because it would likely be disfiguring), 83 percent saw enough tumor regression to undergo breast conserving-surgery rather than mastectomy. And of the four patients originally classified as inoperable (because mastectomy would not remove all the cancer), three saw enough tumor regression to undergo breast-conserving surgery and only one received mastectomy.

Beyond these benefits, aromatase inhibitors do not have the toxic side effects of traditional chemotherapy. And for this particular group of patients, Ellis says it is well established that aromatase inhibitors are more active in preventing relapses than chemotherapy.

In all, 352 women were randomly assigned to receive one of three FDA-approved aromatase inhibitors – letrozole, anastrozole and exemestane. Letrozole and anastrozole were slightly better than exemestane in shrinking tumors. But there were no other differences between the three drugs in surgery rates and in a key measure of how well the drugs stopped cancer cells from dividing, called the Ki67 cell proliferation biomarker.

"These aromatase inhibitors were subject to a lot of debate as to whether one was better than another," Ellis says. "We found some minor differences in the amount of tumor shrinkage the patients experienced. But there was no difference between the three drugs in terms of how effectively they stopped the tumor growing."

Ellis points out that this smaller trial came to the same conclusions as much larger, more expensive trials designed to compare the same drugs. Instead of looking at the final outcome for the patient in the larger trials, Ellis stresses the importance of using biomarkers such as the Ki67 measure of cell division to look at the tumors' biological response to the drugs.

"If we can show the drugs are biologically equivalent with a few hundred patients, we should not waste our time with superiority trials involving thousands of patients comparing the same agents," he says.

But according to Ellis, if one drug is shown to be superior in the smaller trial, then a larger trial to test the outcomes for patients becomes worthwhile.

"This concept is critical in terms of how we target our research investments. Large trials that find no difference between drugs should be avoided as much as possible given the tens of millions of dollars required to complete these studies," he says.

Despite the improved surgical outcomes for some patients in this trial, Ellis points out that many women still required mastectomy because their tumors did not respond adequately to the aromatase inhibitor treatment.

"The biggest question in my mind is how best to treat the aromatase inhibitor-resistant patients," he says. "These patients have poor outcomes and currently there is no known targeted therapy for them. The question of aromatase inhibitor resistance is a critical issue to understand and address therapeutically."

In an effort to find out why certain tumors are resistant to these drugs, Ellis and colleagues at Washington University's Genome Institute just reported the complete tumor and healthy DNA sequences of 50 breast cancer patients enrolled in this trial. Twenty-six of the 50 tumors responded to treatment and 24 tumors did not.

"The patients gifted a sample of their tumor to the study and, because we know whether a tumor is responsive or resistant, we can start doing really profound studies to understand the molecular basis for variation in response," he says. "Ultimately, we hope the genomics instruct which new drugs to use to develop more effective treatment strategies."



INFORMATION:

Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage II to III breast cancer: clinical and biomarker outcomes and the predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. Journal of Clinical Oncology. May 9, 2011

Ellis MJ et al. Analysis of luminal-type breast cancer by massively parallel sequencing. Presented Saturday, Apr. 2, 2011 at the 102nd Annual Meeting of the American Association for Cancer Research in Orlando, FL.

This work was supported by grants from the National Cancer Institute, the Breast Cancer Research Foundation, the Komen St. Louis Affiliate Clinical Trials Grant, and grants to support the American College of Surgeons Oncology Group for the conduct of this trial from Pfizer and Novartis.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Alvin J. Siteman Cancer Center is the only NCI-designated Comprehensive Cancer Center within a 240-mile radius of St. Louis. Siteman Cancer Center is composed of the combined cancer research and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine.


[Attachments] See images for this press release:
Estrogen-lowering drugs reduce mastectomy rates for breast cancer patients

ELSE PRESS RELEASES FROM THIS DATE:

215 Racing Inc./Mostro Di-Potenza Announces Exclusive Rights to Build the Lamborghini Indomable Concept

215 Racing Inc./Mostro Di-Potenza Announces Exclusive Rights to Build the Lamborghini Indomable Concept
2011-05-10
215 Racing Inc. an American Based company, is proud to announce the exclusive rights to build the Lamborghini Indomable Concept created by Design 4 Motion. This design was created by Daniel Chinchilla under the Masters Program sponsored by Lamborghini. The design is a perfect fit for the first offering of 215 to the supercar market. The car will be built by the Sub-company MOSTRO DI-POTENZA and will be renamed The SF22. This name comes from the design influence of the F22 fighter jet, and is incorporated in the car. SF stands for Street Fighter and only 50 of these cars ...

New marker offers hope for more reliable detection of prostate cancer

2011-05-10
A new, promising marker for diagnosing prostate cancer has been discovered by Uppsala researchers with the aid of a unique method developed at the Department of Immunology, Genetics and Pathology. The study, being published this week in the journal Proceedings of the National Academy of Sciences, PNAS, can lead to more reliable diagnoses and fewer unnecessary operations. The PSA marker used for diagnosing prostate cancer today has been criticized for false positive responses, leading to unnecessary operations. There is therefore great interest in finding new and better ...

Health-care providers are prescribing nontraditional medicine

2011-05-10
BOSTON – More than a third of Americans use some form of complementary and alternative medicine (CAM) and that number continues to rise attributed mostly to increases in the use of mind-body therapies (MBT) like yoga, meditation and deep breathing exercises. Prior research suggests that MBT, while used by millions of patients, is still on the fringe of mainstream medical care in America. New research suggests that attitudes are changing. In a study from Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, researchers found that one in 30 Americans ...

Variety is the spice of life for animal movement

2011-05-10
Scientists at Royal Holloway, University of London and the University of Leicester have discovered animals searching for food do not stick to a complicated pattern of movement as previously thought but tend to wander about randomly. It was previously believed that when searching for food, animals move in very peculiar way called a Lévy flight where they move small distances most of the time, but occasionally move a very long distance. This idea was based on studies in which many animals, like albatrosses or sharks, were tracked. However scientists have been analysing ...

Dementia, mild cognitive impairment common in 'oldest old' women

2011-05-10
Mild cognitive impairment, dementia, and their subtypes are common in the "oldest old" women, which includes those 85 years of age and older, according to a report in the May issue of Archives of Neurology, one of the JAMA/Archives journals. The oldest old is "the fastest growing segment of the U.S. population and is expected to increase in number by 40 percent during the next decade alone," the authors write as background information in the article. "Initial evidence suggests that the incidence of all-cause dementia almost doubles with every 5 years of age and that the ...

Evidence insufficient on relationship of modifiable factors with risk of Alzheimer's disease

2011-05-10
The available evidence is insufficient to draw firm conclusions about the association of modifiable factors and risk of Alzheimer's disease (AD), according to a report posted online today that will appear in the September issue of Archives of Neurology, one of the JAMA/Archives journals. Estimates suggest that up to 5.3 million people in this country may have AD, and this number will likely increase as baby boomers grow older. In fact, "age is currently the strongest known risk factor for AD," write the authors. Variation in the apolipoprotein E (APOE) gene is also associated ...

Research identifies risk factors associated with progression of glaucoma

2011-05-10
Elevated pressure inside the eye, cornea thinning, and visual field loss are all markers that glaucoma may progress, according to a report in the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Glaucoma is one of the world's leading causes of permanent vision loss. It is a group of diseases that can lead to damage of the optic nerve and can result in vision loss and blindness. Previous studies of glaucoma risk factors do not always represent the majority of patients or real-world practices in treating them. "The purpose of our study is to verify ...

Study evaluates cost-effectiveness of strategies to treat infant tear-duct obstruction

2011-05-10
When infants' tear ducts are blocked, the decision about when to intervene and the cost-effectiveness of doing so depend on how likely it is the problem will self-resolve, according to a report in the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals. It is not uncommon for babies to be born with blockage of the tear ducts, a condition known as congenital nasolacrimal duct obstruction (NLDO). In many cases, the condition will resolve spontaneously by the time a child is one year old. For affected infants at least six months old, physicians can ...

Colonoscopy screenings may occur more often than recommended; benefit uncertain in some older adults

2011-05-10
Among Medicare beneficiaries, a large portion of colonoscopies for screening purposes are performed more frequently than recommended intervals. But among older patients treated at Veterans Affairs facilities, warranted follow-up colonoscopies for patients with positive fecal blood tests often do not occur, or cause burden when they do. These findings are from two reports posted online today that will appear in the August 8 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Colonoscopy, a screening test used for the detection of colorectal ...

ASG Bowl Partners With Walmart to Offer Discounted Prescription Drugs to Bowling Center Employees

2011-05-10
ASG Bowl, the Official Insurance Partner of Strike Ten Entertainment and the leading distributor of strategic insurance solutions for bowling proprietors nationwide, has announced an exclusive partnership with Walmart to offer discounted prescription pharmaceuticals to bowling proprietors. The program provides bowling center employees with access to more than 300 different prescription pharmaceuticals for just $4/prescription with a 30-day supply, and only $10/prescription with a 90-day supply. Prescription drugs that are currently not included in the program will still ...

LAST 30 PRESS RELEASES:

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model

Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label

Twelve questions to ask your doctor for better brain health in the new year

Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes

Study identifies genetic cause for yellow nail syndrome

New drug to prevent migraine may start working right away

Good news for people with MS: COVID-19 infection not tied to worsening symptoms

Department of Energy announces $179 million for Microelectronics Science Research Centers

Human-related activities continue to threaten global climate and productivity

Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued

Unraveling the power and influence of language

Gene editing tool reduces Alzheimer’s plaque precursor in mice

TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies

Twisted Edison: Bright, elliptically polarized incandescent light

Structural cell protein also directly regulates gene transcription

Breaking boundaries: Researchers isolate quantum coherence in classical light systems

Brain map clarifies neuronal connectivity behind motor function

Researchers find compromised indoor air in homes following Marshall Fire

Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

'Glass fences' hinder Japanese female faculty in international research, study finds

Vector winds forecast by numerical weather prediction models still in need of optimization

New research identifies key cellular mechanism driving Alzheimer’s disease

Trends in buprenorphine dispensing among adolescents and young adults in the US

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

Association of state cannabis legalization with cannabis use disorder and cannabis poisoning

Gestational hypertension, preeclampsia, and eclampsia and future neurological disorders

Adoption of “hospital-at-home” programs remains concentrated among larger, urban, not-for-profit and academic hospitals

Unlocking the mysteries of the human gut

[Press-News.org] Estrogen-lowering drugs reduce mastectomy rates for breast cancer patients